Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Nov-Dec;48(6):629-636.
doi: 10.4103/0253-7613.194867.

Novel strategies for Alzheimer's disease treatment: An overview of anti-amyloid beta monoclonal antibodies

Katarzyna Rygiel  1
Affiliations
Review

Novel strategies for Alzheimer's disease treatment: An overview of anti-amyloid beta monoclonal antibodies

Katarzyna Rygiel. Indian J Pharmacol. 2016 Nov-Dec.

Abstract

Alzheimer's disease (AD) is a multifactorial, progressive neurodegenerative disorder with a poor prognosis, and thus, novel therapies for AD are certainly needed in a growing population of elderly patients or asymptomatic individuals, who are at risk for AD, worldwide. It has been established that some AD biomarkers such as amyloid-beta load in the brain, precede the onset of the disease, by approximately 20 years. Therefore, the therapy to prevent or effectively treat AD has to be initiated before the emergence of symptoms. A goal of this review is to present the results of recent clinical trials on monoclonal antibodies against amyloid beta, used for the treatment of AD and also to address some of the current challenges and emerging strategies to prevent AD. In recent trials, a monoclonal antibody, i.e. solanezumab has shown some beneficial cognitive effects among mild AD patients. Ongoing studies with gantenerumab and crenezumab will examine when exactly the AD treatment, aimed at modifying the disease course has to be started. This review was based on Medline database search for trials on passive anti-AD immunotherapy, for which the main timeframe was set from 2012 to 2015.

Keywords: Alzheimer's disease; amyloid-beta; clinical trials; immunotherapy; monoclonal antibodies.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

References

    1. Apter JT, Shastri K, Pizano K. Update on disease-modifying/preventive therapies in Alzheimer's disease. Curr Geriatr Rep. 2015;4:312–7. - PMC - PubMed
    1. Reiman EM, Langbaum JB, Tariot PN, Lopera F, Bateman RJ, Morris JC, et al. CAP – Advancing the evaluation of preclinical Alzheimer disease treatments. Nat Rev Neurol. 2016;12:56–61. - PMC - PubMed
    1. Miller G. Alzheimer's research. Stopping Alzheimer's before it starts. Science. 2012;337:790–2. - PubMed
    1. Newell KL, Hyman BT, Growdon JH, Hedley-Whyte ET. Application of the National Institute on Aging (NIA)-Reagan Institute criteria for the neuropathological diagnosis of Alzheimer disease. J Neuropathol Exp Neurol. 1999;58:1147–55. - PubMed
    1. Hampel H, Schneider LS, Giacobini E, Kivipelto M, Sindi S, Dubois B, et al. Advances in the therapy of Alzheimer's disease: Targeting amyloid beta and tau and perspectives for the future. Expert Rev Neurother. 2015;15:83–105. - PubMed

MeSH terms